AbbVie, Genmab drug combo cuts lymphoma progression or death risk in study
AbbVie (ABBV) and Genmab (GMAB) reported that their combination treatment for newly diagnosed lymphoma patients reduced the risk of disease progression or death in a late-stage study. The news sent Genmab shares up about 11% in pre-market trading.
Danish biotech company Genmab OMXCOP:GMAB and US drugmaker AbbVie NYSE:ABBV said on Monday that their combination treatment for patients newly diagnosed with a type of lymphoma cut the risk of disease progression or death in a late-stage study. US-listed Genmab shares were up about 11% in…